Inclusion Criteria:

          -  ≥ 18 years old

          -  Weight ≥ 40 kg

          -  Anticipated life expectancy > 3 months prior to lymphodepletion

          -  Karnofsky Performance Score ≥ 70%

          -  Histologically confirmed diagnosis of AML

          -  In complete response (CR) (including CRi/CRp); patients in first, second or subsequent
             CR (including CRi/CRp) are permitted

          -  MRD detected in bone marrow by MFC

          -  Negative pregnancy test (females of childbearing potential only)

          -  Agree to use effective birth control

          -  Left ventricular ejection fraction (LVEF) ≥ 50%

          -  Platelet Count ≥ 20 x 109/L

          -  Prothrombin Time or INR ≤ 1.5 x ULN (unless receiving therapeutic anticoagulation)

          -  Partial Thromboplastin Time ≤ 1.5 x ULN (unless receiving therapeutic anticoagulation)

          -  Hemoglobin ≥ 8.0 g/dL

          -  Creatinine Clearance ≥ 40mL/min

          -  Serum Total Bilirubin ≤ 1.5 x ULN (unless documented Gilbert's Syndrome with Direct
             Bilirubin < 35% of Total Bilirubin)

          -  ALT ≤ 2.5 x ULN

        Exclusion Criteria:

          -  Cytotoxic chemotherapy within 3 weeks

          -  Immune therapy within 4 weeks

          -  Immunosuppressive therapy within 2 weeks (with exceptions)

          -  Investigational treatment or interventional clinical trial within 4 weeks or 5
             half-lives (if known), whichever is longer

          -  Major surgery within 4 weeks and/or not fully recovered from surgery-related
             toxicities

          -  Known hypersensitivity to chemotherapy, other agents, or excipients used in this study

          -  Female patient that is pregnant or lactating/breastfeeding

          -  Ongoing toxicity from prior anti-cancer therapy that have not recovered to ≤ Grade 1
             (with exceptions)

          -  History of chronic or recurrent autoimmune or immune-mediated disease requiring
             steroids or other immunosuppressive treatments (including anti-tumor necrosis factor
             agents)

          -  Active CNS involvement (i.e. leukemic infiltration)

          -  Any other malignancy that requires active therapy

          -  Uncontrolled intercurrent illness (i.e. acute coronary syndrome in the last 6 months)

          -  Active infection with HIV, Hepatitis B or Hepatitis C

        NOTE: other protocol defined inclusion/exclusion criteria may apply.